Full year report 2012 - Nobel Biocare Corporate

More documents

Recommendations

Info

Dividend – The Board of Directors proposes a dividend of CHF 0.20 per registered share (2011: CHF0.15) reflecting the improved net profit of the year and a payout ratio of 44%. It is planned to pay thisdividend out of reserves and in a shareholder-friendly way without deduction of withholding tax. Thepayment date for this dividend, if approved by the AGM, is set for 8 April 2013 (ex-dividend date: 3 April2013, record date: 5 April 2013).Addition to the Board of Directors – To drive the implementation of Nobel Biocare’s strategy, one ofthe priorities of the Board of Directors has been to broaden and strengthen its operational andmanagement expertise, in particular in the area of medical technology and implant-based toothrestoration. Following this priority, the Board of Directors proposes Franz Maier to be elected as aMember of the Board. Franz Maier brings a successful track record of over 20 years in both functionaland general management positions, most recently as an Executive Vice President Sales and Member ofthe Executive Board of Straumann in the medical devices and biotechnology industry. All existingMembers of the Board stand for re-election.OutlookNobel Biocare believes that the market conditions for 2013 will remain difficult, similar to 2012.In this environment, the Company targets to modestly build market share and deliver modest revenuegrowth. Based on this and the initiated measures, and barring any unforeseen events, Nobel Biocareexpects to deliver an EBIT margin improvement of 50 to100 bps at constant exchange rates (CER).Nobel Biocare is moving from ‘rebuilding’ to a phase of continual performance improvements. Withinthe next 3 to 5 years, assuming markets improve beyond 2013 to modest mid-single digit growth, NobelBiocare targets growing at least in line with the market and to improve EBIT margin also continuallybetween 50 to 100 bps per annum at constant exchange rates.Nobel Biocare (NOBN, SIX Swiss Exchange) is a world leader in innovative restorative and esthetic dentalsolutions. As a complete solutions provider, Nobel Biocare offers the most comprehensive range of solutionsfrom tooth to root, for single tooth to fully edentulous indications. The solutions portfolio covers dentalimplants (including the key brands NobelActive ® , Brånemark System ® and NobelReplace ® , individualizedprosthetics and equipment (NobelProcera ® , guided surgery solutions and biomaterials). Nobel Biocare hasapproximately 2’500 employees and recorded revenue of EUR 580.5 million in 2012. The company is headquarteredin Zurich, Switzerland. Production takes place at seven sites located in Canada, Israel, Japan,Sweden, and the US. Nobel Biocare has 34 direct sales organizations.Further information is available from:Süha DemokanInvestor and Corporate RelationsTel: +41 43 211 42 30, +41 79 430 81 46suha.demokan@nobelbiocare.comFull year report 20126/21
The complete Full Year Report 2012 is available in English, while an abridged version of the report isavailable in German. Both documents can be downloaded from the Nobel Biocare website athttp://corporate.nobelbiocare.com/en/investors and http://corporate.nobelbiocare.com/de/investors,respectively. A preliminary PDF version of the Annual Report 2012 in English can be downloaded viawww.nobelbiocare.com or obtained from investor.relations@nobelbiocare.com.As Nobel Biocare is covered by various financial analysts, the company has contracted Vara Research toperiodically update the consensus analysis, based on the estimates of all participating brokerage firms.The most recent analyst consensus can be accessed at any time via the following site:http://corporate.nobelbiocare.com/en/investors/financial-analysis/analyst-consensus.aspx.Investor and analyst presentationAn investor and analyst presentation in English will be held today, 19 February 2013, at 10.00 am CET atthe SIX Swiss Exchange, ConventionPoint, Auditorium, Selnaustrasse 30, Zurich, Switzerland.This presentation can be listened to live via audio-webcast at www.nobelbiocare.com/investors and isalso accessible via telephone conference, using the dial-in numbers below:+41 (0)91 610 56 00 Continental Europe+44 (0)203 059 58 62 UK+1 (1) 631 570 56 13 USAFor additional local dial-in numbers, please Investors section of our website: www.nobelbiocare.com.To ensure timely participation, please call approximately 5–10 minutes prior to the times indicated above.Recording of the webcast will be available on the website shortly after the end of the conference.Financial calendar:Annual General Meeting 28 March 2013Interim Report 1, 2013 25 April 2013Interim Report 2, 2013 22 August 2013Interim Report 3, 2013 07 November 2013Full Year Report 2013 18 February 2014Full year report 20127/21
Page 1 and 2: Media ReleaseFull year report 2012Z
Page 3 and 4: Alpha-Bio Tec (ABT) is targeting cu
Page 5: OsseoCare TM Pro, that was introduc
Page 9 and 10: Selected financial informationin EU
Page 11 and 12: Condensed consolidatedfinancial sta
Page 13 and 14: Balance sheetin EUR ‘000 Note 31
Page 15 and 16: Cash flow statementin EUR ‘000 No
Page 17 and 18: Operating segments are identified g
Page 19 and 20: The share capital may be increased
Page 21: In June 2010, a Canadian company fi

Full year report 2012 - Nobel Biocare Corporate

Create successful ePaper yourself

Delete template?

Save as template?